Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial-Reference-Cited by-同舟云学术

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Published:2009-06 Issue:9681 Volume:373 Page:2125-2135
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Home Philip D,Pocock Stuart J,Beck-Nielsen Henning,Curtis Paula S,Gomis Ramon,Hanefeld Markolf,Jones Nigel P,Komajda Michel,McMurray John JV

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);Lancet,1998

2. Rosiglitazone RECORD study: glucose control outcomes at 18 months;Home;Diabet Med,2007

3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial;Nauck;Diabet Obes Metab,2007

4. Global guideline for Type 2 diabetes,2005

5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34);Lancet,1998

Cited by 1209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoration of GW9662 scaffold with a fragment-like hit via copper-catalyzed azide-alkyne cycloaddition reaction into peroxisome proliferator-activated receptor γ agonists;Tetrahedron Letters;2024-09

2. A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties;European Journal of Medicinal Chemistry;2024-09

3. Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy;Frontiers in Endocrinology;2024-07-30

4. Anti-inflammatory effect of covalent PPARγ ligands that have a hybrid structure of GW9662 and a food-derived cinnamic acid derivative;Bioscience, Biotechnology, and Biochemistry;2024-06-29

5. Treatment adherence and the contemporary approach to treating type 2 diabetes mellitus;Biomedical Papers;2024-06-10